| Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial AC Medeiros-Ribeiro, NE Aikawa, CGS Saad, EFN Yuki, T Pedrosa, ... Nature medicine 27 (10), 1744-1751, 2021 | 191 | 2021 |
| Two-Week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial CSR Araujo, AC Medeiros-Ribeiro, CGS Saad, KR Bonfiglioli, ... Annals of the Rheumatic Diseases 81 (6), 889-897, 2022 | 50 | 2022 |
| Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study LC Netto, KY Ibrahim, CM Picone, APPS Alves, EV Aniceto, MR Santiago, ... The Lancet HIV 9 (5), e323-e331, 2022 | 46 | 2022 |
| Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases NE Aikawa, LVK Kupa, AC Medeiros-Ribeiro, CGS Saad, EFN Yuki, ... Annals of the Rheumatic Diseases 81 (7), 1036-1043, 2022 | 42 | 2022 |
| Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a … NE Aikawa, LVK Kupa, SG Pasoto, AC Medeiros-Ribeiro, EFN Yuki, ... The Lancet Rheumatology 4 (2), e113-e124, 2022 | 29 | 2022 |
| Impact of distinct therapies on antibody response to SARS‐CoV‐2 vaccine in systemic lupus erythematosus EFN Yuki, EF Borba, SG Pasoto, LP Seguro, M Lopes, CGS Saad, ... Arthritis care & research 74 (4), 562-571, 2022 | 26 | 2022 |
| Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis AC Medeiros-Ribeiro, KR Bonfiglioli, DS Domiciano, AY Shimabuco, ... Annals of the Rheumatic Diseases 81 (5), 710-719, 2022 | 22 | 2022 |
| Thalidomide and lenalidomide for refractory systemic/cutaneous lupus erythematosus treatment: a narrative review of literature for clinical practice EFN Yuki, CA Silva, NE Aikawa, R Romiti, CO Heise, E Bonfa, SG Pasoto JCR: Journal of Clinical Rheumatology 27 (6), 248-259, 2021 | 22 | 2021 |
| Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases B Gualano, IR Lemes, RP Silva, AJ Pinto, BC Mazzolani, FI Smaira, ... Brain, behavior, and immunity 101, 49-56, 2022 | 21 | 2022 |
| Systemic autoimmune myopathies: A prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2 SK Shinjo, FHC de Souza, IBP Borges, AM Dos Santos, R Miossi, ... Rheumatology 61 (8), 3351-3361, 2022 | 19 | 2022 |
| Understanding the dynamics of hydroxychloroquine blood levels in lupus nephritis TN Pedrosa, SG Pasoto, NE Aikawa, EFN Yuki, EF Borba, JCRF Filho, ... Lupus 29 (6), 560-568, 2020 | 17 | 2020 |
| Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome F Signorelli, GGM Balbi, NE Aikawa, CA Silva, LVK Kupa, ... Lupus 31 (8), 974-984, 2022 | 14 | 2022 |
| Strong response after fourth dose of mRNA COVID-19 vaccine in autoimmune rheumatic diseases patients with poor response to inactivated vaccine NE Aikawa, LVK Kupa, CA Silva, CGS Saad, SG Pasoto, EFN Yuki, ... Rheumatology (Oxford, England), 2022 | 14 | 2022 |
| Interaction of TNFi and conventional synthetic DMARD in SARS-CoV-2 vaccine response in axial spondyloarthritis and psoriatic arthritis CGS Saad, MSR Silva, PD Sampaio-Barros, JCB Moraes, CG Schainberg, ... Joint bone spine 90 (1), 105464, 2023 | 9 | 2023 |
| Anti-SARS-CoV-2 immunogenicity decay and incident cases six months after Sinovac-CoronaVac inactivated vaccine in autoimmune rheumatic diseases patients: phase 4 prospective trial E Bonfa, C Silva, A Medeiros-Ribeiro, L Kupa, E Yuki, SSG Pasoto, ... | 8 | 2021 |
| Immunogenicity decay and case incidence six months post Sinovac-CoronaVac vaccine in autoimmune rheumatic diseases patients CA Silva, AC Medeiros-Ribeiro, LVK Kupa, EFN Yuki, SG Pasoto, ... Nature communications 13 (1), 5801, 2022 | 5 | 2022 |
| Immunogenicity and safety of primary fractional-dose yellow fever vaccine in autoimmune rheumatic diseases AC Tonacio, T do Nascimento Pedrosa, EF Borba, NE Aikawa, SG Pasoto, ... PLoS Neglected Tropical Diseases 15 (11), e0010002, 2021 | 5 | 2021 |
| Effect of an exercise bout before the booster dose of an inactivated SARS-CoV-2 vaccine on immunogenicity in immunocompromised patients B Gualano, CGS Saad, SM Sieczkowska, ÍR Lemes, RP da Silva, AJ Pinto, ... Journal of Applied Physiology 132 (3), 682-688, 2022 | 4 | 2022 |
| One-year prospective nerve conduction study of thalidomide neuropathy in lupus erythematosus: Incidence, coasting effect and drug plasma levels EFN Yuki, R Soares, LVK Kupa, CO Heise, NE Aikawa, M Arnone, ... Lupus 30 (6), 956-964, 2021 | 4 | 2021 |
| Ankylosing spondylitis and psoriatic arthritis: revisiting screening of latent tuberculosis infection and its follow-up during anti-tumor necrosis factor therapy in an endemic area AY Shimabuco, AC Medeiros-Ribeiro, R Miossi, KR Bonfiglioli, ... Clinics 75, 2020 | 4 | 2020 |
